The list of medicines that cannot be exported, which has 38 fewer medicines than the last one, released in January, includes medicines that were out of stock in February, as well as medicines that are being supplied under the Authorisation of Exceptional Use (AUE).

The list that came into force on 5 March totals 98 presentations of drugs from various categories and active substances, such as methylphenidate (used to treat attention deficit and hyperactivity), propranolol (antihypertensive), azithromycin (antibiotic), cefuroxime (anti-infective/antibacterial) and medicines used by diabetics such as liraglutide (injectable solution in a pre-filled pen) and metformin.

This temporary suspension is intended to ensure the normalisation of the supply of medicines considered critical.

Infarmed monitors information on shortages, disruptions, and sales cessations on a daily basis, to identify and avoid, in a timely manner, critical situations that could affect the availability of medicines.

The national medicines authority is part of the European network of contact points of competent national authorities, the European Medicines Agency (EMA), and the European Commission which, since April 2019, has been used to share information on ruptures supply and availability issues of medicines authorized in the European Union.